Payment overview · 2025
General Payments
$215.25
10 reported records · 6 companies
Healthcare provider profile · identity verified
Leah Burch Rock, MD
Allopathic & Osteopathic Physicians|Family Medicine · RICHTON, MS · NPI 1215434261
Verified facts
What the public records show
CMS Open Payments records show Leah Burch Rock, MD received $215.25 in general payments during 2025 across 10 reported records.
Otsuka America Pharmaceutical, Inc. accounted for 35.7% of that reported general-payment amount.
The Open Payments records used for this analysis explicitly named 8 associated products.
A separate comparison found the same explicitly named product in public Medicare Part D data: Ozempic, Trelegy Ellipta.
ABBVIE INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported LINZESS as an associated drug or biological on 87954 records involving 21815 distinct recipient NPIs. Public Medicare Part D data also shows 63 claims for Linzess by this doctor in 2024.
ABBVIE INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported SYNTHROID as an associated drug or biological on 10655 records involving 4881 distinct recipient NPIs. Public Medicare Part D data also shows 77 claims for Synthroid by this doctor in 2024.
AstraZeneca Pharmaceuticals LP reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported FARXIGA as an associated drug or biological on 106133 records involving 42906 distinct recipient NPIs. Public Medicare Part D data also shows 65 claims for Farxiga by this doctor in 2024.
AstraZeneca Pharmaceuticals LP reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported SYMBICORT as an associated drug or biological on 71 records involving 51 distinct recipient NPIs. Public Medicare Part D data also shows 22 claims for Symbicort by this doctor in 2024.
GlaxoSmithKline, LLC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported SHINGRIX as an associated drug or biological on 43515 records involving 26794 distinct recipient NPIs. Public Medicare Part D data also shows 57 claims for Shingrix by this doctor in 2024.
GlaxoSmithKline, LLC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported TRELEGY ELLIPTA as an associated drug or biological on 131532 records involving 37148 distinct recipient NPIs. Public Medicare Part D data also shows 45 claims for Trelegy Ellipta by this doctor in 2024.
Novo Nordisk Inc reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported Ozempic as an associated drug or biological on 261625 records involving 77793 distinct recipient NPIs. Public Medicare Part D data also shows 131 claims for Ozempic by this doctor in 2024.
These records do not establish that a payment influenced prescribing or medical care.
Separate record types
Research & Ownership
Research Payments (direct recipient): not present in the loaded data
Associated Research Funding (for example, named PI): not present in the loaded data
Ownership / Investment: not present in the loaded data
These categories are never added into the General Payments headline. Associated research funding must not be described as money the doctor personally received unless the source record supports that conclusion.
Who paid this doctor?
Companies in 2025 General Payments
| Reported company | Canonical company | Amount | Share | Records | Year |
|---|---|---|---|---|---|
| Otsuka America Pharmaceutical, Inc. | Unresolved — no canonical attribution shown | $76.80 | 35.7% | 3 | 2025 |
| GlaxoSmithKline, LLC. | Unresolved — no canonical attribution shown | $44.16 | 20.5% | 2 | 2025 |
| AstraZeneca Pharmaceuticals LP | Unresolved — no canonical attribution shown | $31.49 | 14.6% | 2 | 2025 |
| ABBVIE INC. | Unresolved — no canonical attribution shown | $22.41 | 10.4% | 1 | 2025 |
| Novo Nordisk Inc | Unresolved — no canonical attribution shown | $20.66 | 9.6% | 1 | 2025 |
| Exact Sciences Corporation | Unresolved — no canonical attribution shown | $19.73 | 9.2% | 1 | 2025 |
What were the payments for?
Payment categories
| Category | Amount | Records |
|---|---|---|
| Food and Beverage | $215.25 | 10 |
A meal, consulting fee, royalty, and travel payment describe different kinds of reported relationships and should not be interpreted as equivalent.
Analysis 1 · Payment-linked products
Products named in Open Payments records
| Reported product | Type | Reported company | Related amount* | Records | Year |
|---|---|---|---|---|---|
| REXULTI Normalized: rexulti |
Drug | Otsuka America Pharmaceutical, Inc. | $76.80 | 3 | 2025 |
Source payment records
|
|||||
| TRELEGY ELLIPTA Normalized: trelegy ellipta |
Drug | GlaxoSmithKline, LLC. | $44.16 | 2 | 2025 |
Source payment records
|
|||||
| QULIPTA Normalized: qulipta |
Drug | ABBVIE INC. | $22.41 | 1 | 2025 |
Source payment records
|
|||||
| Ozempic Normalized: ozempic |
Drug | Novo Nordisk Inc | $20.66 | 1 | 2025 |
Source payment records
|
|||||
| Rybelsus Normalized: rybelsus |
Drug | Novo Nordisk Inc | $20.66 | 1 | 2025 |
Source payment records
|
|||||
| The Cologuard Plus Collection Kit Normalized: the cologuard plus collection kit |
Device | Exact Sciences Corporation | $19.73 | 1 | 2025 |
Source payment records
|
|||||
| BREZTRI Normalized: breztri |
Drug | AstraZeneca Pharmaceuticals LP | $16.22 | 1 | 2025 |
Source payment records
|
|||||
| AIRSUPRA Normalized: airsupra |
Drug | AstraZeneca Pharmaceuticals LP | $15.27 | 1 | 2025 |
Source payment records
|
|||||
* Product-associated amounts are non-additive because one payment record may name more than one product.
These products were named on specific Open Payments records. A named product does not show that the payment influenced treatment or prescribing.
Public prescribing for products named in payments
| Open Payments product | Payment year | Part D brand | Part D year | Claims | Match method | Source |
|---|---|---|---|---|---|---|
| Ozempic ozempic |
2025 | Ozempic | 2024 | 131 | exact normalized | Medicare Part D |
| TRELEGY ELLIPTA trelegy ellipta |
2025 | Trelegy Ellipta | 2024 | 45 | exact normalized | Medicare Part D |
The presence of the same drug in both datasets does not show that a payment caused or influenced a prescription.
Analysis 2 · Same-company prescribing overlap
Drugs reported in other payments from the same company that also appear in Medicare Part D
This analysis is independent from products named on this doctor’s individual payment records. A row appears only when the exact Open Payments reporting entity paid this doctor, that same reporting entity reported the drug or biological on at least 10 loaded General Payment records involving at least 2 distinct recipient NPIs, and this doctor has the same non-generic brand in public Part D data. This does not mean the company owns or manufactures the drug.
| Paying company | Payment year | Drug reported by same entity | Open Payments evidence | Part D | Claims | Beneficiaries |
|---|---|---|---|---|---|---|
| ABBVIE INC. Exact reporting entity; no affiliate inference |
2025 | LINZESS open payments reported associated product |
CMS Open Payments — General Payments 87954 supporting records · 21815 recipient NPIs · example record 1201352608 |
Linzess · 2024 Exact normalized brand match · 1 Part D row |
63 | 15 |
| ABBVIE INC. Exact reporting entity; no affiliate inference |
2025 | SYNTHROID open payments reported associated product |
CMS Open Payments — General Payments 10655 supporting records · 4881 recipient NPIs · example record 1201352636 |
Synthroid · 2024 Exact normalized brand match · 1 Part D row |
77 | 20 |
| AstraZeneca Pharmaceuticals LP Exact reporting entity; no affiliate inference |
2025 | FARXIGA open payments reported associated product |
CMS Open Payments — General Payments 106133 supporting records · 42906 recipient NPIs · example record 1206131362 |
Farxiga · 2024 Exact normalized brand match · 1 Part D row |
65 | 18 |
| AstraZeneca Pharmaceuticals LP Exact reporting entity; no affiliate inference |
2025 | SYMBICORT open payments reported associated product |
CMS Open Payments — General Payments 71 supporting records · 51 recipient NPIs · example record 1206132610 |
Symbicort · 2024 Exact normalized brand match · 1 Part D row |
22 | suppressed by CMS |
| GlaxoSmithKline, LLC. Exact reporting entity; no affiliate inference |
2025 | SHINGRIX open payments reported associated product |
CMS Open Payments — General Payments 43515 supporting records · 26794 recipient NPIs · example record 1190332452 |
Shingrix · 2024 Exact normalized brand match · 1 Part D row |
57 | 47 |
| GlaxoSmithKline, LLC. Exact reporting entity; no affiliate inference |
2025 | TRELEGY ELLIPTA open payments reported associated product |
CMS Open Payments — General Payments 131532 supporting records · 37148 recipient NPIs · example record 1190332369 |
Trelegy Ellipta · 2024 Exact normalized brand match · 1 Part D row |
45 | 12 |
| Novo Nordisk Inc Exact reporting entity; no affiliate inference |
2025 | Ozempic open payments reported associated product |
CMS Open Payments — General Payments 261625 supporting records · 77793 recipient NPIs · example record 1188130076 |
Ozempic · 2024 Exact normalized brand match · 1 Part D row |
131 | 22 |
These facts do not show that a payment was for the drug, that the company owns or manufactures the drug, or that a payment caused or influenced prescribing.
Public Medicare Part D data
Provider-and-drug rows loaded for 2024
| Brand | Generic | Claims | Beneficiaries |
|---|---|---|---|
| Atorvastatin Calcium | Atorvastatin Calcium | 509 | 138 |
| Amlodipine Besylate | Amlodipine Besylate | 448 | 118 |
| Omeprazole | Omeprazole | 351 | 83 |
| Lisinopril | Lisinopril | 286 | 75 |
| Losartan Potassium | Losartan Potassium | 285 | 83 |
| Rosuvastatin Calcium | Rosuvastatin Calcium | 279 | 82 |
| Gabapentin | Gabapentin | 269 | 84 |
| Pantoprazole Sodium | Pantoprazole Sodium | 232 | 86 |
| Levothyroxine Sodium | Levothyroxine Sodium | 230 | 58 |
| Hydrochlorothiazide | Hydrochlorothiazide | 219 | 62 |
| Fluticasone Propionate | Fluticasone Propionate | 216 | 86 |
| Metformin Hcl | Metformin Hcl | 210 | 49 |
| Albuterol Sulfate Hfa | Albuterol Sulfate | 165 | 66 |
| Sertraline Hcl | Sertraline Hcl | 153 | 47 |
| Metformin Hcl Er | Metformin Hcl | 140 | 34 |
| Furosemide | Furosemide | 135 | 46 |
| Ozempic | Semaglutide | 131 | 22 |
| Famotidine | Famotidine | 127 | 42 |
| Carvedilol | Carvedilol | 123 | 35 |
| Trazodone Hcl | Trazodone Hcl | 122 | 43 |
| Metoprolol Succinate | Metoprolol Succinate | 120 | 37 |
| Meloxicam | Meloxicam | 108 | 36 |
| Alendronate Sodium | Alendronate Sodium | 105 | 31 |
| Fluoxetine Hcl | Fluoxetine Hcl | 104 | 31 |
| Montelukast Sodium | Montelukast Sodium | 102 | 31 |
| Potassium Chloride | Potassium Chloride | 100 | 27 |
| Allopurinol | Allopurinol | 98 | 27 |
| Hydrocodone-Acetaminophen | Hydrocodone/Acetaminophen | 98 | 20 |
| Jardiance | Empagliflozin | 96 | 24 |
| Clopidogrel | Clopidogrel Bisulfate | 95 | 25 |
| Pravastatin Sodium | Pravastatin Sodium | 95 | 32 |
| Glimepiride | Glimepiride | 93 | 26 |
| Lisinopril-Hydrochlorothiazide | Lisinopril/Hydrochlorothiazide | 89 | 20 |
| Metoprolol Tartrate | Metoprolol Tartrate | 88 | 21 |
| Citalopram Hbr | Citalopram Hydrobromide | 84 | 22 |
| Cyclobenzaprine Hcl | Cyclobenzaprine Hcl | 83 | 34 |
| Synthroid | Levothyroxine Sodium | 77 | 20 |
| Bupropion Xl | Bupropion Hcl | 74 | 20 |
| Duloxetine Hcl | Duloxetine Hcl | 74 | 19 |
| Tamsulosin Hcl | Tamsulosin Hcl | 74 | 24 |
| Eliquis | Apixaban | 71 | 16 |
| Ondansetron Hcl | Ondansetron Hcl | 69 | 27 |
| Simvastatin | Simvastatin | 66 | 14 |
| Farxiga | Dapagliflozin Propanediol | 65 | 18 |
| Valsartan | Valsartan | 64 | 14 |
| Linzess | Linaclotide | 63 | 15 |
| Escitalopram Oxalate | Escitalopram Oxalate | 61 | 16 |
| Tramadol Hcl | Tramadol Hcl | 59 | 16 |
| Donepezil Hcl | Donepezil Hcl | 57 | 15 |
| Shingrix | Varicella-Zoster Ge/As01b/Pf | 57 | 47 |
| Diclofenac Sodium | Diclofenac Sodium | 56 | 28 |
| Amitriptyline Hcl | Amitriptyline Hcl | 54 | 19 |
| Ezetimibe | Ezetimibe | 53 | 17 |
| Zolpidem Tartrate | Zolpidem Tartrate | 52 | 16 |
| Amoxicillin-Clavulanate Potass | Amoxicillin/Potassium Clav | 51 | 46 |
| Buspirone Hcl | Buspirone Hcl | 51 | 17 |
| Clonazepam | Clonazepam | 51 | suppressed |
| Pioglitazone Hcl | Pioglitazone Hcl | 50 | 15 |
| Tizanidine Hcl | Tizanidine Hcl | 50 | 18 |
| Pregabalin | Pregabalin | 47 | 14 |
| Doxycycline Hyclate | Doxycycline Hyclate | 46 | 36 |
| Oxybutynin Chloride Er | Oxybutynin Chloride | 46 | 11 |
| Trelegy Ellipta | Fluticasone/Umeclidin/Vilanter | 45 | 12 |
| Spironolactone | Spironolactone | 44 | 15 |
| Hydroxyzine Hcl | Hydroxyzine Hcl | 42 | 15 |
| Prednisone | Prednisone | 42 | 21 |
| Azithromycin | Azithromycin | 41 | 33 |
| Estradiol | Estradiol | 41 | 17 |
| Primidone | Primidone | 41 | suppressed |
| Meclizine Hcl | Meclizine Hcl | 39 | 16 |
| Januvia | Sitagliptin Phosphate | 38 | suppressed |
| Venlafaxine Hcl Er | Venlafaxine Hcl | 37 | 11 |
| Esomeprazole Magnesium | Esomeprazole Magnesium | 36 | suppressed |
| Paroxetine Hcl | Paroxetine Hcl | 36 | suppressed |
| Levocetirizine Dihydrochloride | Levocetirizine Dihydrochloride | 34 | 12 |
| Megestrol Acetate | Megestrol Acetate | 34 | suppressed |
| Ropinirole Hcl | Ropinirole Hcl | 34 | 11 |
| Topiramate | Topiramate | 33 | suppressed |
| Cefdinir | Cefdinir | 32 | 26 |
| Warfarin Sodium | Warfarin Sodium | 31 | suppressed |
| Atenolol | Atenolol | 30 | suppressed |
| Hydroxyzine Pamoate | Hydroxyzine Pamoate | 30 | 14 |
| Oxybutynin Chloride | Oxybutynin Chloride | 30 | suppressed |
| Promethazine Hcl | Promethazine Hcl | 30 | 15 |
| Lorazepam | Lorazepam | 29 | suppressed |
| Losartan-Hydrochlorothiazide | Losartan/Hydrochlorothiazide | 29 | suppressed |
| Memantine Hcl | Memantine Hcl | 29 | suppressed |
| Quetiapine Fumarate | Quetiapine Fumarate | 29 | suppressed |
| Baclofen | Baclofen | 28 | suppressed |
| Hydralazine Hcl | Hydralazine Hcl | 27 | suppressed |
| Methocarbamol | Methocarbamol | 27 | 12 |
| Myrbetriq | Mirabegron | 27 | suppressed |
| Oxycodone-Acetaminophen | Oxycodone Hcl/Acetaminophen | 27 | 11 |
| Benztropine Mesylate | Benztropine Mesylate | 26 | suppressed |
| Breztri Aerosphere | Budesonide/Glycopyr/Formoterol | 26 | suppressed |
| Cephalexin | Cephalexin | 26 | 17 |
| Fenofibrate | Fenofibrate Nanocrystallized | 26 | suppressed |
| Methylprednisolone | Methylprednisolone | 26 | 26 |
| Doxepin Hcl | Doxepin Hcl | 25 | suppressed |
| Fenofibrate | Fenofibrate | 25 | suppressed |
| Fluconazole | Fluconazole | 25 | 19 |
| Mounjaro | Tirzepatide | 25 | suppressed |
| Clonidine Hcl | Clonidine Hcl | 24 | 12 |
| Mupirocin | Mupirocin | 24 | 15 |
| Nystatin | Nystatin | 24 | 14 |
| Acetaminophen-Codeine | Acetaminophen With Codeine | 23 | suppressed |
| Bisoprolol-Hydrochlorothiazide | Bisoprolol/Hydrochlorothiazide | 23 | suppressed |
| Dicyclomine Hcl | Dicyclomine Hcl | 23 | suppressed |
| Finasteride | Finasteride | 23 | suppressed |
| Alprazolam | Alprazolam | 22 | suppressed |
| Lantus Solostar | Insulin Glargine,hum.Rec.Anlog | 22 | suppressed |
| Mirtazapine | Mirtazapine | 22 | suppressed |
| Propranolol Hcl | Propranolol Hcl | 22 | suppressed |
| Symbicort | Budesonide/Formoterol Fumarate | 22 | suppressed |
| Triamterene-Hydrochlorothiazid | Triamterene/Hydrochlorothiazid | 22 | suppressed |
| Enalapril Maleate | Enalapril Maleate | 21 | suppressed |
| Fluticasone-Salmeterol | Fluticasone Propion/Salmeterol | 21 | suppressed |
| Ketoconazole | Ketoconazole | 21 | suppressed |
| Olanzapine | Olanzapine | 21 | suppressed |
| Sulfamethoxazole-Trimethoprim | Sulfamethoxazole/Trimethoprim | 21 | 17 |
| Triamcinolone Acetonide | Triamcinolone Acetonide | 20 | 12 |
| Butalbital-Acetaminophen-Caffe | Butalb/Acetaminophen/Caffeine | 19 | suppressed |
| Vitamin D2 | Ergocalciferol (Vitamin D2) | 19 | suppressed |
| Clotrimazole-Betamethasone | Clotrimazole/Betamethasone Dip | 18 | suppressed |
| Enulose | Lactulose | 18 | suppressed |
| Cyanocobalamin Injection | Cyanocobalamin (Vitamin B-12) | 17 | suppressed |
| Glipizide Er | Glipizide | 17 | suppressed |
| Dropsafe Prep Pads | Alcohol Antiseptic Pads | 16 | suppressed |
| Levofloxacin | Levofloxacin | 16 | 13 |
| Valsartan-Hydrochlorothiazide | Valsartan/Hydrochlorothiazide | 16 | suppressed |
| Ondansetron Odt | Ondansetron | 15 | suppressed |
| Spironolactone-Hctz | Spironolact/Hydrochlorothiazid | 15 | suppressed |
| Ultra-Fine Mini Pen Needle | Pen Needle, Diabetic | 15 | suppressed |
| Benazepril Hcl | Benazepril Hcl | 14 | suppressed |
| Celecoxib | Celecoxib | 14 | suppressed |
| Cyproheptadine Hcl | Cyproheptadine Hcl | 14 | suppressed |
| Desvenlafaxine Succinate Er | Desvenlafaxine Succinate | 14 | suppressed |
| Bupropion Hcl Sr | Bupropion Hcl | 13 | suppressed |
| Clonidine | Clonidine | 13 | suppressed |
| Eszopiclone | Eszopiclone | 13 | suppressed |
| Medroxyprogesterone Acetate | Medroxyprogesterone Acetate | 13 | suppressed |
| Nebivolol Hcl | Nebivolol Hcl | 13 | suppressed |
| Nitrofurantoin Mono-Macro | Nitrofurantoin Monohyd/M-Cryst | 13 | 11 |
| Toujeo Max Solostar | Insulin Glargine,hum.Rec.Anlog | 13 | suppressed |
| Amiodarone Hcl | Amiodarone Hcl | 12 | suppressed |
| Colchicine | Colchicine | 12 | suppressed |
| Divalproex Sodium | Divalproex Sodium | 12 | suppressed |
| Indapamide | Indapamide | 12 | suppressed |
| Phenytoin | Phenytoin | 12 | suppressed |
| Raloxifene Hcl | Raloxifene Hcl | 12 | suppressed |
| Sumatriptan Succinate | Sumatriptan Succinate | 12 | suppressed |
| Entresto | Sacubitril/Valsartan | 11 | suppressed |
| Gemfibrozil | Gemfibrozil | 11 | suppressed |
| Incruse Ellipta | Umeclidinium Bromide | 11 | suppressed |
| Irbesartan-Hydrochlorothiazide | Irbesartan/Hydrochlorothiazide | 11 | suppressed |
| Klor-Con M20 | Potassium Chloride | 11 | suppressed |
| Lansoprazole | Lansoprazole | 11 | suppressed |
| Nortriptyline Hcl | Nortriptyline Hcl | 11 | suppressed |
| Novolog Flexpen | Insulin Aspart | 11 | suppressed |
| Novolog Mix 70-30 | Insulin Aspart Prot/Insuln Asp | 11 | suppressed |
| Paxlovid | Nirmatrelvir/Ritonavir | 11 | 11 |
| Verapamil Er | Verapamil Hcl | 11 | suppressed |
Timeline
Payment and prescribing data by year
Open Payments and Medicare Part D may refer to different years. They are shown separately rather than aligned as if they describe the same period.
| Year | General Payments | Main payer | Explicit products | Company overlaps | Part D coverage |
|---|---|---|---|---|---|
| 2025 | $215.25 · 10 records | Otsuka America Pharmaceutical, Inc. | AIRSUPRA, BREZTRI, Ozempic, QULIPTA, REXULTI, Rybelsus, TRELEGY ELLIPTA, The Cologuard Plus Collection Kit | 7 | — |
| 2024 | — | — | — | — | Complete |
Questions to ask
Questions you could discuss with your doctor
- What role, if any, does Ozempic play in your treatment recommendations for me?
- How do you evaluate evidence when you have a financial relationship with ABBVIE INC.?
- Are there reasonable alternatives I should understand when we discuss treatment options?
- How should I interpret the industry-payment records shown here in the context of my care?
These are general questions generated from reviewed templates. They are not personalized medical advice.
Sources and limitations
How to read this page
- Payment and Medicare prescribing data can cover different years; every comparison shows both years explicitly.
- Part D does not represent a doctor’s entire practice; it excludes many patients and is subject to CMS public-release thresholds.
- Company–drug relationships must have an auditable source, a precise relationship type, and a valid evidence period. Unresolved mappings are not published.
- Generic drug claims are not attributed to a specific manufacturer without manufacturer-level evidence.
- When a source extract is incomplete, missing rows are never treated as proof of no payments or no prescriptions.
Loaded source releases
| Dataset | Year | Publication | Source |
|---|---|---|---|
| CMS Open Payments — General Payments | 2025 | 2026-06-30 | Original source |
| Medicare Part D Prescribers by Provider and Drug | 2024 | 2026-05-06 | Original source |
| NPPES Data Dissemination V2 | current / reference data | 2026-08-10 | Original source |
Full methodology · Questions & answers · Report a possible error